je.st
news
Tag: cancer
Interim Results from Phase 1b/2 Study Evaluating the Combination of Mercks KEYTRUDA (pembrolizumab) and Eisais HALAVEN (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS
2016-12-12 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with Eisais microtubule dynamics inhibitor, HALAVEN (eribulin), in patients with metastatic triple-negative breast cancer (TNBC). Language: English Contact: Media:MerckPamela Eisele, 267-305-3558orKim Hamilton, (908) 740-1863orEisai Inc.Laurie Landau, 201-746-2510orInvestors:MerckTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898orEisai Inc.Ivor Macleod, 201-746-2660 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: results
study
presented
combination
KEYTRUDA (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
2016-12-07 08:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. First Presentation of Patient-Reported Outcomes from KEYNOTE-024 Study of Patients with Metastatic NSCLC Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) Findings Presented in Plenary Session at 17 th World Conference on Lung Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive health-related quality of life (HRQoL) findings from an exploratory analysis from the phase 3 KEYNOTE-024 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, compared to standard of care (SOC) platinum-containing chemotherapy for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 (tumor proportion score [TPS] of Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: life
quality
cell
treatment
Updated KEYTRUDA (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
2016-12-06 14:20:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients. Language: English Contact: Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestorsTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
CSPI requests cancer warning labels on processed meat
2016-12-05 15:29:00| National Hog Farmer
Food police seek cancer warning labels on processed meats; Congress looks to wrap up 2016; farm income down third year in a row; biodiesel tax extenders idling; Pelosi holds off challenge. read more
Tags: warning
requests
cancer
processed
New KEYTRUDA (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies
2016-11-30 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings to be Presented in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Malignant Pleural Mesothelioma with KEYTRUDA as Monotherapy and in Combination with Other Treatments Quality of Life Data from KEYNOTE-024 in First-Line Non-Small Cell Lung Cancer to be Presented in Plenary Session KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, across multiple thoracic malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer and malignant pleural mesothelioma, will be presented at the 17th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Vienna, Austria, Dec. Language: English Contact: Media Contacts:Pamela Eisele, (267) 305-3558orKim Hamilton, (908) 740-1863orInvestor Contacts:Teri Loxam, (908) 740-1986orAmy Klug, (908) 740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] next »